External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry
Background: To be useful across the broadest range of patients and clinical settings, clinical prediction models should be externally validated in different data sets and clinical settings and refined over time. In 2022, the HoLISTIC Consortium (www.hodgkinconsortium.org) developed and validated the...
Gespeichert in:
Veröffentlicht in: | Blood 2023-11, Vol.142 (Supplement 1), p.6200-6200 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: To be useful across the broadest range of patients and clinical settings, clinical prediction models should be externally validated in different data sets and clinical settings and refined over time. In 2022, the HoLISTIC Consortium (www.hodgkinconsortium.org) developed and validated the A-HIPI model via TRIPOD guidelines for adults 18-65 with advanced stage classic Hodgkin Lymphoma (AS-HL) (Rodday et al., JCO 2023). The A-HIPI model, based on individual patient (pt) data from more than 5000 patients (pts) from North America, Europe, and Australia, predicts progression-free survival and overall survival within the first 5 years (PFS5 and OS5) based on pre-treatment pt and disease characteristics (www.qxmd.com/calculate/calculator_869/a-hipi). In collaboration with Brazilian clinical experts and researchers, we describe the performance of the A-HIPI in the Brazilian Prospective HL registry.
Methods: The Brazilian Prospective HL registry (NCT02589548) was originally established in 2009 with the goal of evaluating risk factors, treatment, and disease outcomes. By 2022, 1357 pts with classic HL were registered with a median follow-up of 5 years for surviving patients (Biasoli I. HemaSphere 2022). 5-year PFS and OS were calculated using the Kaplan-Meier method. Using the methodology for validation and calibration outlined in by Rodday et al., calculated risk scores were calculated for PFS5 and OS5. Harrell c-statistic and the Uno c-statistic were calculated to evaluate discrimination (i.e., differentiation of those at higher risk of having an event from those at lower risk) and plots of deciles of predicted vs. observed outcomes were created to assess calibration (i.e., how similar the predicted absolute risk of the model is to the true (observed) risk in an external cohort). In the primary A-HIPI analysis, laboratory values outside of permitted range were excluded and not imputed. This was checked in sensitivity analysis using multiple imputation for missing values; no substantial differences were noted. Thus, in the current validation, out-of-range lab values were excluded. There were no exclusions in the current analysis for early death, defined as deaths that occurred from the onset of first treatment until 30 days after its end. Pts with HIV were excluded from the assembled cohort.
Results: 694 patients with AS-HL with the inclusion criteria of the original study were included in the present study. The median age was 30.9 years (range, 18-65) a |
---|---|
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2023-173318 |